Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.54 |
| ▸ | DRD3 | P35462 | 5/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939782 | 0.87 | DRD2 (0.51) | DRD2DRD3DRD4LMNAKDM1A | |
| SCHEMBL2080862 | 0.82 | DRD3 (0.60) | DRD2DRD3DRD4 | |
| SCHEMBL7354100 | 0.79 | DRD2 (0.59) | DRD2DRD3CYP1A2CYP3A4HRH3 | |
| SCHEMBL936624 | 0.77 | HTR2C (0.54) | DRD2LMNAKDM1ARCOR1 | |
| SCHEMBL6493903 | 0.77 | HTR2C (0.54) | DRD2LMNAKDM1ARCOR1 | |
| SCHEMBL7784267 | 0.77 | HTR2C (0.54) | DRD2LMNAKDM1ARCOR1 | |
| SCHEMBL2077442 | 0.77 | DRD3 (0.70) | DRD2DRD3 | |
| SCHEMBL3836737 | 0.75 | DRD2 (0.66) | DRD2DRD3DRD4CYP3A4 | |
| SCHEMBL2081044 | 0.75 | DRD2 (0.51) | DRD2DRD3LMNA | |
| SCHEMBL3154991 | 0.74 | DRD2 (0.56) | DRD2DRD3DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-7576081-B2 | Central nervous system disorders ; sexual disorders; hypotensive agents; analgesics; neurodegenerative disease; obesity; Alzheimer's disease; obsessive compulsive disorders; antidepressants | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576081-B2 | Central nervous system disorders ; sexual disorders; hypotensive agents; analgesics; neurodegenerative disease; obesity; Alzheimer's disease; obsessive compulsive disorders; antidepressants | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | DRD2 16/4885DRD3 35/4885DRD4 50/4885 |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | DRD2 10/4885DRD3 19/4885DRD4 29/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | DRD2 13/4885DRD3 26/4885DRD4 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.